# Estimation of the Prevalence of HER2 Low and Describe the SoC, Treatment Patterns, and Outcome in Real-world Practice Among Unresectable and/or Metastatic Breast Cancer Patients With HER2 Low Status

> **NCT04807595** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 798 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **OTHER:** None (Observational study)

## Key facts

- **NCT ID:** NCT04807595
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-28
- **Primary completion:** 2022-04-26
- **Final completion:** 2022-04-26
- **Target enrollment:** 798 (ACTUAL)
- **Last updated:** 2023-03-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04807595

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04807595, "Estimation of the Prevalence of HER2 Low and Describe the SoC, Treatment Patterns, and Outcome in Real-world Practice Among Unresectable and/or Metastatic Breast Cancer Patients With HER2 Low Status". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04807595. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*